Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial (2015)
- Authors:
- Hurvitz, Sara A.
- Andre, Fabrice
- Jiang, Zefei
- Shao, Zhimin
- Mano, Max S.
- Neciosup, Silvia P.
- Tseng, Ling-Min
- Zhang, Qingyuan
- Shen, Kunwei
- Liu, Donggeng
- Dreosti, Lydia M.
- Burris, Howard A.
- Toi, Masakazu
- Buyse, Marc E.
- Cabaribere, David
- Lindsay, Mary-Ann
- Rao, Shantha
- Pacaud, Lida Bubuteishvili
- Taran, Tetiana
- Slamon, Dennis
- Autor USP: MANO, MAX SENNA - FM
- Unidade: FM
- DOI: 10.1016/S1470-2045(15)00051-0
- Subjects: ESTUDOS RANDOMIZADOS; PLACEBO; NEOPLASIAS MAMÁRIAS (TERAPIA); ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: The Lancet Oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 16, n. 7, p. 816-829, 2015
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
HURVITZ, Sara A. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet Oncology, v. 16, n. 7, p. 816-829, 2015Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(15)00051-0. Acesso em: 02 jan. 2026. -
APA
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., et al. (2015). Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet Oncology, 16( 7), 816-829. doi:10.1016/S1470-2045(15)00051-0 -
NLM
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial [Internet]. The Lancet Oncology. 2015 ; 16( 7): 816-829.[citado 2026 jan. 02 ] Available from: https://doi.org/10.1016/S1470-2045(15)00051-0 -
Vancouver
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial [Internet]. The Lancet Oncology. 2015 ; 16( 7): 816-829.[citado 2026 jan. 02 ] Available from: https://doi.org/10.1016/S1470-2045(15)00051-0 - Value of systemic staging in asymptomatic early breast cancer
- Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
- Reply to [Carta]: mastectomy skin flap thickness
- O uso do Oncotype DX® na indicação de quimioterapia adjuvante - experiência do Hospital Sírio-Libanês
- Pneumonite não-infecciosa em paciente com tumor neuroendócrino tratado com everolimus (EVR)
- Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
- A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
- HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
- Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America
- Malignancy-related hypercalcemia in the bishosphonate era
Informações sobre o DOI: 10.1016/S1470-2045(15)00051-0 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
